Close Menu

NEW YORK – Precision oncology company Repare Therapeutics is homing in on synthetic lethality as a jumping off point for developing new cancer therapies.

Using a CRISPR-Cas9 genome editing-based screening platform, the company is aiming to discover novel pathways and patient subsets, and develop treatments that selectively affect DNA damage response mechanisms in cancer cells and kill them, while sparing normal cells.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
21

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.